Audit: QRS - Tesamorelin for Health & Longevity

Audit conducted on 08/08/2026 00:51 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every protocol figure (1.28 mg daily, 2 mg predecessors, 1-2 mg off-label, bedtime/30 min, quadrant rotation, 5 cm navel margin), every time-to-effect value, all 9 contraindications, all 10 interactions, all 11 biomarker targets, the cadence, and all 7 qualitative markers trace to ER lines 404-442, 470-494, 532, 556-582.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	ER’s hedged framings are carried through: “conflicted evidence on cognitive performance”, “conflicted evidence on an early rise in blood glucose”, “theoretical promotion of occult neoplasia”, “splitting the dose is counterproductive and untested”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy and breastfeeding remain in the Contraindications gate, not the Key Interactions gate; the Speculative tiers stay speculative; the conflicted glucose and cognition signals keep their conflict marker.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from ER “Populations who should avoid tesamorelin” (lines 426-442) and Key Interactions only from the ER interaction bullets (lines 404-422); no Benefit- or Risk-Modifying Factor content is surfaced in either gate or in the Risks card.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, no NCT identifiers, no expert names. The only brand name, “Egrifta WR”, appears in the Protocol cell for the same fact as ER line 472.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighted register throughout, matching the ER’s own framing of a well-supported fat-loss effect against an open longevity question.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets and thresholds carry the data-driven register; the At-A-Glance and Qualitative Assessment cards keep it accessible and actionable.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive, impersonal constructions throughout (“Reconstituted solution is inspected for particles before use”); no prescriptions are issued to a named reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader; the Protocol and Monitoring cards report established practice rather than instructing.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should”, or “we suggest” anywhere in the sheet.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns appear anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to the biomarker table where they are the measured quantities themselves; the At-A-Glance card is fully de-jargonised.
2.8	Information is presented in a concise and very compact manner	🟢	Each benefit and risk tier is compressed to a single semicolon-separated line; interaction and contraindication items are stripped to the key fact.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan: no “you”, “your”, or “yourself”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range biomarker targets, z-score titration, and imaging-based response definitions address exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Daily subcutaneous injection with quadrant rotation, front-loaded laboratory cadence, and repeat imaging at 6 and 12 months are presented without hedging on burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Functional targets sit well inside conventional laboratory reference ranges (e.g., ALT below 25 U/L, hs-CRP below 0.5 mg/L), which is a signal aimed at the optimizing audience rather than the general population.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The Speculative risk “Unfavorable long-term effect on longevity from sustained IGF-1 elevation” and the At-A-Glance closing line preserve the specifically longevity-relevant counterweight to the body-composition benefit.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Anti-aging” does not occur; the header and At-A-Glance use “Health & Longevity” and “lengthens life”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Injected subcutaneously”, “peripheral edema”, “paresthesia, hypoesthesia”, “hypersensitivity reactions”, “injection site reactions” — formal register throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All six card/section headings, both gate headings, all four tier labels in both the Benefits and Risks cards, and all three Monitoring column headers are present verbatim (lines 445, 494, 544, 578, 609, 644, 679, 683-685, 861).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	74 data-qrs-var spans present, each occurring exactly once, covering page_title, header_, at_a_glance, stop_items, caution_items, action_1-3, time_1-3, benefits_, risks_*, marker_1-11, monitoring_cadence, and qualitative_item_1-7.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable template constructs (<span website="evidence_review">, <span website="audit">, <span website="full_review">), the footer disclaimer, the stylesheet link, and the structural comments are all untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty: Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Therapeutic Protocol, and Monitoring Protocol & Defining Success are all fully populated.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard approved protocol”, “Best time of day”, and “Injection technique” reproduce the ER bold labels at lines 472, 478, and 484 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit, risk, and biomarker labels track the ER headings and table rows; the only removals are the ER’s “Absolute contraindication —” / “Avoid —” category prefixes and the “— caution” / “— monitor” trailing qualifiers, which items 8.4 and 9.4 require to be stripped.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-text scan returns no characters above U+2190; the ER’s 🟩/🟥/🟨/⚠️ markers are rendered as CSS palettes and the phrase “conflicted evidence on”.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against the ER: 17 ER benefit sub-sections collapse into 4 lines, 17 risk sub-sections into 4 lines, and every interaction and contraindication is stripped to its key fact with all magnitudes, rationale, and mitigation text removed.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The comment opens at line 2, immediately after <!doctype html> on line 1, and closes at line 14 before any other markup.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3 and closing --- at line 13, preceded by the permitted comment text “QRS — Metadata (invisible, parsed by audit tooling)”.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	It sits wholly inside an HTML comment and none of its values are echoed anywhere in <head> or <body>.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values are trimmed and unquoted except duration: "00:04", whose colon requires YAML quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: tesamorelin_2026-0807-2155_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0808-0037, conforming to the required format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version suffix or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no additional qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: tesamorelin_2026-0807-2155_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all ten keys, including git_user: evipedia-1 and git_issue: 4927; no stray whitespace and no unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Tesamorelin for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Tesamorelin for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/08/2026, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0808-0037.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header contains only the title and the standard subline; the ER’s “Also known as” line (Egrifta, Egrifta SV, Egrifta WR, TH9507, Tesamorelin Acetate) is correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All five sentences condense ER Conclusion lines 606-608: mechanism, best-supported effect, population and sponsorship limits, loss of benefit on stopping, open longevity question.
7.2	[at_a_glance] is no longer than 60 words	🟢	54 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion passage: line 606 for the mechanism and the fat/liver/lean triad, line 606 for the enrollment and sponsorship caveats, line 608 for benefit fading and for the open longevity question.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“HIV” is rendered “a chronic immune-system virus”, “GHRH” as “the brain signal that prompts growth hormone release”, “visceral adipose tissue” as “deep abdominal fat”; no acronym appears.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, participant count, or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Magnitudes are given qualitatively (“marked loss”, “less liver fat”, “modest lean-tissue gain”); no numbers, confidence intervals, or risk ratios.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items come from the “Populations who should avoid tesamorelin” list at ER lines 424-442, inside that section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All nine ER entries are present and none is invented: pituitary axis disruption, malignancy, hypersensitivity, pregnancy/breastfeeding, poorly controlled diabetes, elevated IGF-1, acute critical illness, unstable cardiac disease, and under 18.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Nine discrete <li> elements inside the stop_items span at lines 580-605.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationale is stripped throughout (e.g., “no data exist and the drug acts on an axis that is still developmentally active” and “based on excess mortality observed with growth hormone in intensive care” are both dropped); no dash-introduced clause remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within the preceding 24 months”, “other than non-melanoma skin cancer”, “HbA1c above 8%”, “active proliferative or severe non-proliferative retinopathy”, “z-score above 2.0 before treatment”, and the full pituitary and cardiac qualifier lists are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER contraindication bullets use no ranking notation inside parentheses.
8.7	If no [stop_items] are present the section is left empty	N/A	Nine stop items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items come from the interaction bullets at ER lines 404-422.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interaction bullets are represented and none duplicates a contraindication item.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten discrete <li> elements inside the caution_items span at lines 611-635.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER trailing qualifier is stripped (“— caution, dose adjustment likely”, “— monitor”, “— caution, reduced effect”, “— avoid combination”, “— minor, timing-relevant”, “— no action required”) along with all Consequence and Mitigation prose.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All named example lists are retained in full: the four glucocorticoids, the glucose-lowering agents with glipizide and semaglutide, both thyroid agents, both oral estrogen forms, all six secretagogues, both NSAIDs, all seven additive supplements, all four glucose supplements, and both CYP3A4 substrates.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets use no ranking notation inside parentheses; all parentheticals are plain comma-separated drug lists.
9.7	If no [caution_items] are present the section is left empty	N/A	Ten caution items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER “Therapeutic Protocol” lines 470-494.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing, and injection technique are the three decision-bearing implementation aspects; the remaining ER bullets are background (half-life, genotype, sex, age) or duplicate Monitoring content.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Protocol section supplies well over three actionable aspects and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content: labels from the ER bold labels, values “1.28 mg daily” / “Bedtime” / “Rotate abdominal quadrants”, and subs condensing ER lines 472, 476, 478, 482, and 484.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Deep abdominal fat, liver fat, and IGF-1 are exactly the three timelines the ER gives at “Time to effect” (line 532).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered deep abdominal fat, liver fat, IGF-1 — matching the ER High-tier benefit ordering, which leads with the pooled -27.7 cm² visceral fat effect.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are present in the ER and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans are populated from ER line 532: “3 to 6 months”, “12 months”, “2 to 4 weeks”, with subs reproducing the imaging detectability window, the 12-month liver measurement, and the scale-weight caveat.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides an explicit “Time to effect” bullet, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All fifteen listed benefits map one-to-one onto the ER Expected Benefits sub-headings at lines 162-250.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present at lines 546, 552, 559, and 565, each populated with its correct tier.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a bare semicolon-separated list of the ER headings; none of the ER Magnitude figures (-27.7 cm², -4.1%, +1.42 kg, +108 ng/mL, r = 0.56) or narrative rationale is carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s “(Visceral)” parenthetical in “Reduction of Deep Abdominal (Visceral) Fat” is stripped, and no other parenthetical survives.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seventeen listed risks map one-to-one onto the ER sub-headings at lines 276-378.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present at lines 646, 653, 660, and 667, each populated with its correct tier.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a bare semicolon-separated list; none of the ER frequency figures (8.5% vs 2.7%, 13.3% vs 11.7%, risk ratio 2.25) or explanatory prose is carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear anywhere in the four risk tiers.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER “Monitoring Protocol & Defining Success” biomarker table at lines 560-572.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eleven ER rows are present in ER order: IGF-1, fasting glucose, HbA1c, fasting insulin and HOMA-IR, ALT, triglycerides, hs-CRP, TSH with free T4, visceral fat area, hepatic fat fraction, waist circumference. Targets and “Why” text match the ER verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 850-855 reproduce the full ER cadence at line 558, including the 2- and 6-week checks, the 3-month interval, the 6- and 12-month imaging, and annual cancer screening.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All seven items come from the “Qualitative markers worth tracking alongside the laboratory panel” list at ER lines 574-582.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER markers are present in ER order with their bold labels verbatim: morning ankle and hand swelling, joint stiffness and aching, numbness or tingling in the fingers, depth and continuity of sleep, waistband fit, recovery and daytime energy, and injection site condition.

Issues 08/08/2026 00:51

Pass rate 100.00%. No issues found.

Issues 08/08/2026 00:44

1. 4.5 — Six unclosed pcell divs: Each of the six .pcell blocks in the Protocol and Time-to-effect rows closes only one </div> after its .sub span (lines 460, 474, 488, 507, 519, 532), so the body has 44 opening and 38 closing <div> tags against the template’s 44/44; the cells nest inside one another and the three-column grid collapses off the single page.
2. 9.4 — Trailing action clauses not stripped: Eight Key Interactions items carry the ER’s post-em-dash clause through as a trailing colon phrase — “: dose adjustment likely” (line 608), “: monitor” (612, 614, 628), “: reduced effect” (615), “: avoid combination” (618), “: timing-relevant” (621), “: no action required” (630) — where the checklist requires just the key fact.

Fixes 08/08/2026 00:44

1. 4.5 — Restored six unclosed pcell divs: Added the missing </div> that closes each .pcell after its .sub block in the three Protocol cells and three Time-to-effect cells; the body now has 44 opening and 44 closing <div> tags, matching the template, so the three-column grid no longer collapses.
2. 9.4 — Stripped trailing action clauses: Removed the carried-over post-em-dash clauses from eight Key Interactions items (“: dose adjustment likely”, “: monitor” ×3, “: reduced effect”, “: avoid combination”, “: timing-relevant”, “: no action required”), leaving only the drug class and its parenthetical example list.